Cytori Therapeutics Inc Warrant
CYTXW
CYTXW was delisted on the 14th of December, 2018.
6 hedge funds and large institutions have $2.48M invested in Cytori Therapeutics Inc Warrant in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.
43% more capital invested
Capital invested by funds: $1.74M → $2.48M (+$744K)
20% more funds holding
Funds holding: 5 → 6 (+1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Creative Planning
Overland Park,
Kansas
|
+$17.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$90.4K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$207 |
CYTXW Hedge Fund Activity: Q3 2016 in Review
6 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Cytori Therapeutics Inc Warrant (CYTXW) for Q3 2016, worth a combined $2.48M — up 43% from $1.74M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new CYTXW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Creative Planning, opening a new position worth an estimated $17.1K. The largest seller was Sabby Management, cutting an estimated $90.4K.
- 6 institutional investors held Cytori Therapeutics Inc Warrant (CYTXW) as of Q3 2016, up from 5 in Q2 2016.
- Funds reported $2.48M of Cytori Therapeutics Inc Warrant stock for Q3 2016, up 43% quarter-over-quarter.
- 1 fund opened new Cytori Therapeutics Inc Warrant positions in Q3 2016 and 0 closed out, a net change of +1 holder.
- The largest Cytori Therapeutics Inc Warrant buyer in Q3 2016 was Creative Planning, an estimated $17.1K added.
- The largest Cytori Therapeutics Inc Warrant seller in Q3 2016 was Sabby Management, an estimated $90.4K sold.
Based on aggregated 13F filings for Q3 2016.